Drug intelligence / Profile preview

metronidazole + mezlocillin

Development stage
Unknown
Lead developer
Pfizer
Modality
Small Molecules
Administration
Intravenous, Intramuscular
01

Overview

Metronidazole + mezlocillin is a combination of two antibiotics used primarily for the treatment and prophylaxis of mixed aerobic and anaerobic bacterial infections, especially in surgical settings such as colon surgery. Metronidazole is a nitroimidazole antibiotic effective against anaerobic bacteria and certain protozoa by disrupting DNA synthesis. Mezlocillin is an extended-spectrum penicillin (antipseudomonal penicillin) that inhibits bacterial cell wall synthesis, targeting a broad range of Gram-negative and some Gram-positive organisms. The combination provides synergistic activity against both facultative and obligate anaerobes, including Enterococci, Klebsiella pneumoniae, Escherichia coli, Pseudomonas aeruginosa, Bacteroides species, Clostridium species, Fusobacterium species, Peptococcus and Peptostreptococcus[1][2][3][6]. This regimen is often used for perioperative prophylaxis in abdominal surgeries to reduce postoperative infection rates[2].

Other names
metronidazole plus mezlocillinmetronidazole/mezlocillin
02

Targets

PBP (Penicillin-binding protein family)

Beyond the preview

Go deeper on metronidazole + mezlocillin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on metronidazole + mezlocillin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call